Krishna Institute of Medical Sciences has intimated stock exchanges of a forthcoming Board of Directors meeting scheduled for Friday, May 15, 2026. The notice, filed pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, states that the board will convene to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Board Meeting Details

The following key details have been disclosed in the regulatory filing:

Trading Window Closure

In accordance with the Company's Code of Conduct for the Prevention of Insider Trading, Krishna Institute of Medical Sciences has also disclosed the status of its trading window. The key details are as follows:

• The trading window for dealing in the company's shares was closed with effect from Wednesday, April 1, 2026.
• The trading window will remain closed until 48 hours after the announcement of the financial results for the quarter and financial year ended March 31, 2026.
• This restriction applies to all Directors, Officers, Designated Persons, and Connected Persons of the company.

The regulatory intimation was signed by Nagajayanthi J.R, Company Secretary & Compliance Officer of Krishna Institute of Medical Sciences, and was dated May 06, 2026.

Krishna Institute of Medical Sciences Limited has entered into a strategic clinical collaboration through a Memorandum of Understanding (MoU) with Dakshayani Healthcare Services Private Limited, as disclosed under Regulation 30 on April 23, 2026. The partnership focuses on enhancing oncology care services and improving patient outcomes through a comprehensive non-commercial brand association agreement.

Partnership Structure and Strategic Focus

The collaboration represents a non-commercial brand association between KIMS and Dakshayani Healthcare Services Private Limited, also known as "Renova." Renova is described as a specialized oncology organization with proprietary clinical protocols and expertise in cancer research and academic supervision, with extensive experience in managing cancer centers across India. The partnership specifically emphasizes oncology care enhancement and patient outcome improvement.

Collaboration Framework and Patient Care Enhancement

Under this arrangement, both KIMS and Renova will collaborate on a mutual, non-commercial basis with a dedicated focus on patient outcomes. Renova will share its clinical expertise, knowledge, and best practices in oncology care with KIMS. The association is specifically designed to strengthen healthcare delivery standards, particularly in oncology services, while ensuring enhanced patient care outcomes through collaborative clinical protocols.

Strategic Benefits and Outcomes

The partnership creates comprehensive mutual benefits for both organizations while prioritizing patient care improvement. Renova will enhance its brand positioning through association with Krishna Institute of Medical Sciences, while KIMS will benefit from and foster the collaborative development of clinical protocols and treatment methodologies with Renova. This strategic alliance aims to advance oncology care standards and deliver superior patient outcomes.

Regulatory Compliance and Market Disclosure

The company has informed both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) about this strategic collaboration pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The association is expected to contribute positively to the overall service quality, patient care outcomes, and reputation of the company in the healthcare sector. The official communication was signed by Dr. Nagajayanthi J R, Company Secretary and Compliance Officer, confirming the formal nature of this strategic partnership.